PPT-Validation of serological biomarkers for detection of non-alcoholic fatty liver disease

Author : byron | Published Date : 2024-10-04

Carolyn Yanavich Antônio Pacheco Sandra W Cardoso Estevão Portela Ursula B Chaves Ricardo Santos Michelle Morata Valdilea G Veloso Beatriz Grinsztejn Hugo

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Validation of serological biomarkers for..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Validation of serological biomarkers for detection of non-alcoholic fatty liver disease: Transcript


Carolyn Yanavich Antônio Pacheco Sandra W Cardoso Estevão Portela Ursula B Chaves Ricardo Santos Michelle Morata Valdilea G Veloso Beatriz Grinsztejn Hugo Perazzo National Institute of . Prof. Sandeep Garg. Department of Medicine. Maulana Azad Medical College. New Delhi. INDIA. INTRODUCTION. Non-alcoholic fatty liver disease (NAFLD) - most common cause of chronic liver disease in developed countries (prevalence of 20–30% in the adult population).. Look for it Children and adolescents-. Too!. Dr. . Shrish. . Bhatnagar. Consultant Pediatric Gastroenterologist. VPIMS & . ELMCH,Lucknow. Dedication. JNMC. SGPGIMS. Dr S K BHATNAGAR. Hepatomegaly. Masi. . Khaja. , M.D. Objectives . Epidemiology. Natural History. Clinical Presentation. Pathogenesis. Approach to Diagnosis. Treatment. What is NAFLD?. Nonalcoholic Fatty Liver Disease. [NAFLD]. STEATOSIS. Katharine K. Roberts, MD. UCSD Transplant Hepatology Fellow. 9/30/2017. Disclosures. None. Objectives. Define NAFLD and its subtypes. Differentiate between simple steatosis and steatohepatitis. Discuss the pathogenesis of . non-alcoholic fatty liver disease. Dr. . Abdulwahhab. S. Abdullah. CABM, FICMS-G&H. Alcoholic liver . disease. Alcoholic liver . disease (ALD) is . one of the most common causes of . chronic liver disease worldwide.. adults. Dr.mousavi. -Abadan-. Khordad. 1397 . DEFINITIONS — Patients with nonalcoholic fatty liver disease (NAFLD) . have hepatic . steatosis. , . with or without . inflammation and fibrosis. . In addition, . Case 3.13. 1. Chapter 3. Fatty Liver Diseases. Clinical Presentation. A 46-year-old woman with a history of chronic alcohol intake and hypothyroidism presented with symptoms of alcohol withdrawal.. Physical exam revealed jaundice, palmar erythema, spider angioma, and telangiectasia formation over her face. . About these slides. These slides provide highlights of new data presented at the EASL NAFLD Summit 2019. Please feel free to use, adapt and share these slides for your own personal use; however, please acknowledge EASL as the source. G4 and Management Subodh Kumar 1 , Uday Narayan Singh 2 REVIEW ARTICLE Liver detoxi�es the various metabolic products inside the body and converts toxic substance to less toxic by different Information for Patients April 2021 | www.hepatitis.va.gov What is Non-Alcoholic Fatty Liver Disease? Non-alcoholic fatty liver disease or NAFLD is when fat is increased in the liver and there is n  . Hideki Fujii. 1. , Shinya Fukumoto. 1. , Masaru Enomoto. 2. , Sawako Uchida-Kobayashi. 2. , Tatsuo Kimura. 1. , Akihiro Tamori. 2. , Yuji Nadatani. 1. , Shingo Takashima. 1. , Naoki Nishimoto. 3. Rohit . Pai. MD, FRCPC. Gastroenterology and Hepatology. Island Health and Pacific Digestive Health. Clinical Assistant Professor, UBC. Liver Care Clinic, Royal . Jubillee. Hospital. Disclosures. Research: Intercept. Download PDF The Fatty Liver Solution™ eBook by Duncan Capicchiano - A natural and effective approach to tackling fatty liver disease. Diabetes. Hypertension. HDL < 1 . mmol. /L . Triglycerides > 1.7 . mmol. /L. Suspicion of NAFLD ?. Remember normal LFT’s do not rule out liver disease Exclude significant alcohol misuse (intermediate or high risk group in the alcohol related liver disease pathway) before diagnosing NAFLD via this pathway.

Download Document

Here is the link to download the presentation.
"Validation of serological biomarkers for detection of non-alcoholic fatty liver disease"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents